Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
Drugs in Context, 2015 Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan +2 more
doaj +2 more sources
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection [PDF]
Scientific Reports, 2021 Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations.
Agata Antepowicz +5 more
doaj +2 more sources
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain [PDF]
BMC Infectious Diseases, 2017 Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna +6 more
doaj +2 more sources
International Journal of General Medicine, 2018 Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj +1 more source
Journal of Pediatric and Neonatal Individualized Medicine, 2015 Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route.
Karel Allegaert +3 more
doaj +2 more sources
RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. [PDF]
Health Sci RepABSTRACT Background New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants.
Tuckerman J +8 more
europepmc +2 more sources
BMC Infectious DiseasesAim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj +2 more sources
Palivizumab for Donor-Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report. [PDF]
Respirol Case RepWe describe the use of off‐label palivizumab in an early post‐operative bilateral lung transplant recipient with probable donor‐derived RSV who developed persistent severe LRTI and respiratory failure. RSV PCR Ct fell and remained low from day 0 to day 42 despite conventional therapy until palivizumab was administered on day 44, following which we ...
Meharry R, Vale C, Mackintosh J.
europepmc +2 more sources
The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis. [PDF]
Acta PaediatrABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Heinonen S, Vartiainen P.
europepmc +2 more sources
Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention. [PDF]
Pediatr InvestigPediatric Investigation, Volume 10, Issue 4, Page 293-299, August 2026.
Wang R, Abu-Raya B, Obeid H, Xie Z.
europepmc +2 more sources